share_log

JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30

Benzinga ·  Aug 1 02:32  · Ratings

JP Morgan analyst Robbie Marcus maintains AtriCure (NASDAQ:ATRC) with a Overweight and lowers the price target from $34 to $30.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment